In reference to IL-7/CCL19-engineered mesothelin-redirected CAR-Ts, it was reported that the adoptive transfer of these CAR-Ts to a pancreatic cancer patient led to the complete elimination of tumors almost 8 months following CAR-T treatment (151). This evidence concerns the gene CCL19 and familial pancreatic carcinoma.